Cancer Institute A national cancer institute
designated cancer center

Willard ("Bill") E. Fee, Jr.

Publication Details

  • Cis-platinum chemotherapy in head and neck cancers. Otolaryngology Jacobs, C., Bertino, J. R., Goffinet, D. R., Fee, W. E., Goode, R. L. 1978; 86 (5): ORL-780 3

    Abstract:

    Sixteen patients with advanced head and neck carcinomas were treated with cis-diaminedichloro platinum chemotherapy; seven preoperatively and nine for recurrent disease. Cis-platinum was given by 24-hour infusions of 80 mg/m2 every three weeks. There was 50% regression in 38% (6) of the patients; another 38% (6) had 25% to 50% regression. Toxicity was minimal, with vomiting occurring in 75% (12) of the courses, renal toxicity in 6% (2), leukopenia in 13% (4), thrombocytopenia in 9% (3), and anemia in 31% (10). Of the seven patients who had serial audiograms, only one experienced ototoxicity. Cis-platinum, given by 24-hour infusion, was effective in reducing tumor bulk in 75% (12) of the patients, with advanced head and neck carcinomas, without undue morbidity.

    View details for PubMedID 114948

Stanford Medicine Resources:

Footer Links: